CION Ameerpet
Understanding Immunotherapy & the Decision
Who Is Eligible for Immunotherapy — and Who Is Not
Most people who ask about immunotherapy are hoping for a yes — and most, when formally evaluated, are told it isn't the right option for them right now. NCCN and ASCO guidance ties eligibility to a specific, testable combination of cancer type, biomarker status and overall fitness, not to how advanced the disease is or how much a patient wants it to work. Understanding that combination — and what a "no" actually means — is the first honest step in this decision.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- Eligibility is a checklist, not a feeling — the decision rests on testable criteria: approved indication, biomarker status, fitness and organ function.
- Most patients evaluated are not candidates — being told immunotherapy isn't right for you says nothing about how hard your team is fighting for you.
- A matching biomarker alone isn't enough — overall fitness, organ function and other treatments already tried all factor into the final call.
- Not eligible today doesn't always mean never — retesting, disease changes or a new approval can shift the picture later.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Decision framework
What Actually Decides Whether You're Eligible for Immunotherapy?
Eligibility is decided by four things together, not one: whether immunotherapy is an approved option for your exact cancer type and stage, whether your tumour or blood shows the biomarker that treatment is approved against, whether your overall fitness and organ function can tolerate it, and whether any contraindication rules it out. Most patients evaluated do not meet all four at once.
Approved indication
Immunotherapy is approved only for specific cancer types and stages, based on regulatory approval and guideline bodies such as NCCN, ASCO and CDSCO — not for cancer in general.
Biomarker status
Many indications require a specific biomarker result from a tumour or blood sample — a marker that predicts a reasonable likelihood of benefit for that particular cancer type.
Fitness and organ function
Adequate performance status — how well you manage daily activities — plus healthy liver, kidney and other organ function are usually required to safely receive treatment.
No active contraindication
Uncontrolled autoimmune disease, a recent organ transplant, or high-dose steroids for another condition can rule out immunotherapy even when everything else fits.
This is the general framework oncology teams use — your own tumor board weighs these four factors together for your specific diagnosis, not as a simple pass/fail form.
Did you know?
Meeting one part of the eligibility picture — like having the right biomarker — does not automatically mean immunotherapy will be recommended. All four factors are weighed together, and any one of them can be the reason a team says no.
Approved indications, in general terms
Which Cancers and Stages Is Immunotherapy Actually Considered For?
Checkpoint-inhibitor immunotherapy is approved for a specific, growing list of cancer types and stages — commonly certain lung, kidney, bladder, skin (melanoma), head & neck and gastrointestinal cancers with a matching biomarker — usually from locally advanced through metastatic stages, rarely for very early, fully resectable disease. The list changes as new approvals are added, so it should always be checked against your specific diagnosis rather than assumed.
| Cancer type | Stage typically considered | Biomarker usually required? |
|---|---|---|
| Non-small cell lung cancer | Locally advanced or metastatic | Often yes — PD-L1 expression |
| Melanoma | Advanced or metastatic; some high-risk earlier-stage cases | Sometimes considered without a specific biomarker |
| Kidney cancer (renal cell carcinoma) | Advanced or metastatic | Not always biomarker-dependent |
| Urothelial (bladder) cancer | Locally advanced or metastatic | Often yes — PD-L1 expression |
| Head & neck cancer | Recurrent or metastatic | Often yes — PD-L1 (CPS) |
| Colorectal, gastric & endometrial cancers | Advanced or metastatic | Yes — MSI-high/dMMR status specifically |
This is general, guideline-level information, not a determination for your case. Whether your specific stage and biomarker result qualify is decided by your oncology team against current approvals in India.
The harder conversation
Why Was I Told I'm Not Eligible for Immunotherapy?
The most common reasons are: your cancer type or stage isn't an approved indication yet, your biomarker test came back negative for the marker that treatment requires, your overall fitness or organ function isn't strong enough right now, or you have an active condition — like uncontrolled autoimmune disease — that treatment could seriously worsen. None of these reasons reflect how hard your team is trying, or predict how your cancer will respond to other treatments.
- Cancer type or stage isn't an approved indication — immunotherapy hasn't been approved for every cancer type, and some early, fully resectable cancers don't need it at all.
- Biomarker test came back negative — a negative result for the specific marker a treatment requires usually rules that option out, even if other markers look different.
- Fitness or organ function isn't strong enough right now — this can sometimes improve with time and supportive care, and be reassessed later.
- An active contraindication is present — uncontrolled autoimmune disease, a recent transplant, or high-dose steroids for another condition can make treatment unsafe.
- You've already tried the approved sequence — some approvals apply only after specific earlier treatments have been tried and haven't worked.
Not eligible for immunotherapy is not the same as nothing more can be done. Depending on your cancer type and stage, your oncology team can usually discuss other evidence-based options — chemotherapy, targeted therapy, radiation, surgery, or supportive care focused on comfort and quality of life.
For a genuinely small number of patients, careful monitoring without active treatment can also be a reasonable, informed choice. A second opinion is always reasonable if a "no" doesn't sit right with you.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a Clear, Honest Read on Your Eligibility
A tumor-board review looks at your actual reports — not assumptions — before telling you where you stand.
How the decision is actually made
How Your Eligibility Is Reviewed, Step by Step
Eligibility isn't decided in a single conversation — it typically moves through five steps: confirming the exact diagnosis and stage, biomarker testing, checking overall fitness and organ function, a full case review by a tumor board rather than one doctor, and then a clear conversation about the result, whichever way it goes.
- 1
Confirm the exact diagnosis and stage
Pathology and imaging reports are reviewed in detail, since even one stage's difference can change what's approved.
- 2
Biomarker testing, if your cancer type needs it
The correct test — such as PD-L1 or MSI/MMR — is ordered and processed at an accredited laboratory.
- 3
Fitness and organ-function check
Bloodwork, performance status and any relevant organ-function tests are reviewed against treatment requirements.
- 4
Full tumor board review
A multidisciplinary team, not one doctor, weighs all four eligibility factors together against your specific case.
- 5
A clear conversation about the result
Whether the answer is yes or no, you're told the specific reasons and what your realistic next options are.
Did you know?
A biomarker test result isn't permanent evidence for every future decision — if your cancer changes, a repeat test at a later point can occasionally give a different answer than an earlier one did.
Setting expectations honestly
Common Misunderstandings About Immunotherapy Eligibility
"Immunotherapy is only for stage 4 or terminal cancer." This isn't accurate — some earlier, high-risk cancers are also approved for immunotherapy, and being offered it is not a marker of how advanced your disease is. See Is Immunotherapy Only for Stage 4 Cancer? for the specifics.
"It's basically an immunity booster, so it should help anyone." Checkpoint-inhibitor immunotherapy works through a specific, targeted mechanism against cancer cells — it is not a general immune-system tonic, and treating it as one leads to real disappointment. Our page on Immunotherapy Is Not an Immunity Booster explains the difference in plain terms.
"If my cancer type is approved, I'll automatically get it." Approval for a cancer type only opens the door — your individual biomarker result, fitness and organ function still decide whether you personally qualify.
Decisions led by a team
Eligibility Decided by a Tumor Board, Not One Opinion
Every eligibility question at CION goes through a multidisciplinary tumor board — not a single doctor's snap judgment.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Immunotherapy Eligibility: Your Questions Answered
What actually decides whether I'm eligible for immunotherapy?
Eligibility rests on four factors weighed together, not one: whether immunotherapy is an approved option for your exact cancer type and stage, whether your tumour or blood shows the specific biomarker that treatment requires, whether your overall fitness and organ function can safely tolerate it, and whether you have any active contraindication such as uncontrolled autoimmune disease. Most patients evaluated do not meet all four at once, which is why a tumor board reviews the full picture rather than a single test result.
Which cancers and stages is immunotherapy usually considered for?
Checkpoint-inhibitor immunotherapy is approved for a specific and growing list of cancer types, commonly including certain lung, kidney, bladder, skin (melanoma), head & neck, and select gastrointestinal cancers, usually from locally advanced through metastatic stages. Some cancers also require a specific biomarker result, such as PD-L1 expression or MSI-high/dMMR status, before the treatment applies. The exact, current list should always be checked against your specific diagnosis with your oncology team rather than assumed from general information.
Why was I told I'm not eligible for immunotherapy?
The most common reasons are that your cancer type or stage isn't yet an approved indication, your biomarker test came back negative for the specific marker that treatment requires, your current fitness or organ function isn't strong enough, you have an active contraindication like uncontrolled autoimmune disease, or you haven't yet tried an earlier treatment step that the approval requires first. None of these reasons reflect how hard your team is working for you or predict how you will respond to other available treatments.
If I'm not eligible now, could that change later?
Yes, in some situations. Fitness and organ function can improve with time and supportive care and be reassessed later; a repeat biomarker test on a new tissue or blood sample can occasionally give a different result than an earlier one; and new approvals for your cancer type are added periodically as evidence develops. None of this is guaranteed, but "not eligible today" is not always the final word — it's worth asking your oncologist when, or whether, reassessment makes sense for you.
Does having the right biomarker guarantee immunotherapy will be recommended?
No. A matching biomarker result is only one of several factors — it makes a discussion about immunotherapy worthwhile, but your oncology team still weighs your cancer type and stage, overall fitness, organ function, other treatments you've already had, and any contraindications before recommending it. A favourable biomarker on its own does not confirm eligibility or predict how well treatment would work for you individually.
What are my options if immunotherapy isn't right for me?
Being told you're not eligible for immunotherapy is not the same as being told nothing more can be done. Depending on your cancer type and stage, your oncology team can usually discuss other evidence-based options — chemotherapy, targeted therapy, radiation, surgery, or supportive care focused on comfort and quality of life — and for a genuinely small number of patients, careful monitoring without active treatment can be a reasonable, informed choice. A second opinion is always reasonable if a "no" doesn't sit right with you.